#United States #New York #Securities Fraud #Lawsuit #Altimmune

Class Action Lawsuit Against Altimmune, Inc.

In recent developments, Altimmune, Inc. (NASDAQ: ALT) finds itself in the spotlight due to alleged violations of securities laws, raising concerns among its investors. The law firm Levi & Korsinsky, LLP has issued a public notice informing affected parties of a class action lawsuit initiated on August 26, 2025. This legal action targets investors who may have suffered financial losses attributed to securities fraud incidents that transpired from August 10, 2023, to June 25, 2025.

Background of the Case

The lawsuit is rooted in allegations that Altimmune misled its investors regarding the performance and viability of its investigational products. A significant trigger for these claims was a press release released by the Company on June 26, 2025, which reported the topline results from the pivotal IMPACT Phase 2b MASH trial assessing Pemvidutide, a treatment for metabolic dysfunction associated with non-alcoholic steatohepatitis (NASH).

Despite forecasts of positive results, the reports indicated a disappointing failure to meet the expected statistical significance concerning fibrosis reduction - a primary endpoint of the trial. Media and market analysts had anticipated more favorable outcomes based on the information provided by Altimmune prior to the announcement. This sharp contrast left many investors alarmed, especially when they discovered that the higher-than-anticipated placebo response significantly undermined the Company’s claims.

Stock Value Plummet

The immediate aftermath of the announcement was stark. Following the press release, Altimmune's stock price plummeted dramatically, marking a staggering decline of 53.2% overnight—from $7.71 per share to just $3.61. This swift drop prompted urgent communication from shareholders, pressing for accountability and clarity surrounding the negligence perceived in the announcements leading up to the trial results.

Legal Options for Investors

For investors who feel aggrieved by these developments, it is crucial to act promptly. Levi & Korsinsky has emphasized that those who endured losses from August 10, 2023, through June 25, 2025, should take this opportunity to seek legal redress. The lawsuit class is expected to be finalized by October 6, 2025, which sets a firm deadline for affected investors to engage with the legal team to discuss their rights. Participation in the class action comes at no financial expense to the investor, meaning any potential compensation does not require upfront investment.

The firm has a well-established reputation, having secured hundreds of millions in settlements for clients over the past two decades, including a consistent presence in the ISS Securities Class Action Services' Top 50 Report, reflecting its prominence in the field of securities litigation.

Next Steps for Investors

Being part of the class does not necessitate serving as a lead plaintiff; rather, concerned shareholders are encouraged to connect with Levi & Korsinsky to explore their individual circumstances. Investors can reach out directly via email or phone, seeking guidance on how to proceed with their claims.

As Altimmune navigates this legal turmoil, the situation serves as a reminder of the innate risks involved in investments that can be exacerbated by inadequate transparency and unforeseen test outcomes. The legal proceedings can play a crucial role in addressing these concerns and may also offer a pathway to financial recovery for potentially harmed investors.

For further assistance, interested parties can contact:

Joseph E. Levi, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

It is essential for investors to stay informed as this situation evolves and to utilize all available resources to protect their financial interests.